Antibiotic options for treating community-acquired MRSA

References

• Ogston A. Micrococcus poisoning. J. Anat.17, 24–58 (1882).
   Google Scholar
• Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol.10, 226–236 (1929).
   Google Scholar
• Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature146, 758–759 (1940).
   Google Scholar
• Tomasz A. Weapons of microbial drug resistance abound in soil flora. Science311, 342–343 (2006).
   PubMed Web of Science ®Google Scholar
• Jevrons MP. “Celbenin”-resistant staphylococci. Br. Med. J.1, 124–125 (1961).
   Google Scholar
• Barber M. Methicillin-resistant staphylocci. J. Clin. Path.14, 385–393 (1961).
   PubMed Web of Science ®Google Scholar
• Jevons MP, Coe AW, Parker MT. Methicillin resistance in Staphylococcus aureus.Lancet1(7287), 904–907 (1963).
   PubMed Web of Science ®Google Scholar
• Schmitz FJ, Lindenlauf E, Hoffman E et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. Br. Soc. Antmicrob. Chemother.42, 489–495 (1998).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother.40, 135–136 (1997).
   PubMed Web of Science ®Google Scholar
• Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinopristin–dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopepticles. J. Clin. Microbiol.39, 3586–3590 (2001).
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet358, 207–208 (2001).
   PubMed Web of Science ®Google Scholar
• CDC. Staphylococcus aureus resistant to vancomycin – United States 2002. MMWR Morb. Mortal. Wkly Rep.51, 902 (2003).
   Google Scholar
• Hayden MK, Rezai K, Hayes RA et al. Development of daptomycin resistance in vitro in methicillin resistant Staphylococcus aureus. J. Clin. Microbiol.43, 5285–5307 (2005).
   PubMed Web of Science ®Google Scholar
• Panton PN, Valentine MB. Staphylococcal toxin. Lancet1, 506–508 (1932).
   Google Scholar
• Magure EP, Arthur AD, Boustead PJ et al. Emerging epidemic of community acquired methicillin resistant Staphylococcus aureus infection in the Northern Territory. Med. J. Aust.164, 721–723 (1996).
   PubMed Web of Science ®Google Scholar
• McDougal LK, Steward CD, Killgore GE et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol.41, 5113–5120 (2003).
   PubMed Web of Science ®Google Scholar
• Diep BA, Gill SR, Chang RF et al. Complete genome sequence of USA 300, acquired methicillin resistant Staphylococcus aureus. Lancet367, 731–739 (2006).
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ et al; Emerging ID Net Study Group. Methicillin-resistant S.aureus infections among patients in the emergency department. N. Engl. J. Med.355, 666–674 (2006).
   PubMed Web of Science ®Google Scholar
• Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton–Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatments with antimicrobials inhibiting exotoxin production. Chest128, 2732–2738 (2005).
   PubMed Web of Science ®Google Scholar
• Bahrain M, Vasiliades M, Wolff Y, Younus F. Five cases of bacterial endocrinditis after furonculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections. Scand. J. Infect. Dis.38, 702–707 (2006).
   PubMed Web of Science ®Google Scholar
• Saiman L, O’Keefe M, Graham III PL et al. Hospital transmission of community-acquired, methicillin-resistant Staphylococcus aureus among post partum women. Clin. Infect. Dis.37, 1313–1319 (2003).
   PubMed Web of Science ®Google Scholar
• Kourbatova EV, Halvosa JS, King MD et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am. J. Infect. Control33, 385–389 (2005).
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 genotype as a major cause of health care-associated infections. Clin. Infect. Dis.42, 647–656 (2006).
   PubMed Web of Science ®Google Scholar
• Sauermann R, Rothenburger M, Graninger W. Daptomycin: a review 4 years after first approval. Pharmacology81, 79–81 (2008).
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH. Pharmacokinetic/pharmacodynamic profile for tigecycline – a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect Dis.52, 165–171 (2005).
   PubMed Web of Science ®Google Scholar
• Narita M, Tsuji B, Yu V. Linezolid-associated peripheral and optic neuropathy, lactic acidosis and serotonin syndrome. Pharmacotherapy27, 1189–1197 (2007).
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother.51(Suppl. S2), ii17–ii25 (2003).
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Rybak MJ, Cheung CM et al. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diag. Microbiol. Infect Dis.58, 41–47 (2007).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int. J. Antimicrob. Agents24, 567–571 (2004).
   PubMed Web of Science ®Google Scholar
• Graber CJ, Wong MK, Carleton HA et al. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg. Infect. Dis.13, 491–493 (2007).
   PubMed Web of Science ®Google Scholar
• Gauduchon V, Cozon G, Vandenesch F et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by immunoglobulin in vitro.J. Infect. Dis.189(2), 346–354 (2004).
   PubMed Web of Science ®Google Scholar
• Wardenburg JB, Bae T, Otto M et al. Poring over pores α hemolysin and Panton–Valentine leukocidin in Staphylococcus aureus pneumonia. Nature Med.13, 1405–1406 (2007).
   PubMed Web of Science ®Google Scholar
• Wardenburg JB, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med.205, 287–294 (2008).
   PubMed Web of Science ®Google Scholar
• Davis SL, Perri MB, Donabedian SM et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol.45(6), 1705–1711 (2007).
   PubMed Web of Science ®Google Scholar
• Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis.46, 584–593 (2008).
   PubMed Web of Science ®Google Scholar
• Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureusinfections. Pharmacotherapy27, 227–249 (2007).
   PubMed Web of Science ®Google Scholar
• Billeter M, Zervos MJ, Chen AY et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin. Infect. Dis.46, 577–583 (2008).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis.46(5), 647–655 (2008).
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy of complicated skin and skin structure infections. Antimicrob. Agents Chemother.51, 3612–3616 (2007).
   PubMed Web of Science ®Google Scholar
• Lane H, Weiss L. Bernardi A et al.In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with fulate inhibitors and other antimicrobial with different mechanisms of action. J. Antimicrob. Chemother.60, 1391–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Crum NF, Lee RU, Thornton SA et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am. J. Med.199, 943–951 (2006).
   Google Scholar
• Fidkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med.325, 1435–1444 (2005).
   Google Scholar
• Huang H, Flynn, NM, King JH et al. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-acquired MRSA infections in Sacramento, California. J. Clin. Microbiol.44, 2423–2427 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Saeed S, Pawlak J et al. Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new? Infect. Control Hosp. Epidemiol.27, 133–138 (2006).
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ, Amjad M et al. Antimicrobial susceptibility and staphylococcal chromosomal mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus. Pharmacotherapy27, 3–10 (2007).
   PubMed Web of Science ®Google Scholar
• Naimi TS, LeDell KH, Boxrud DJ et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996–1998. Clin. Infect. Dis.33, 990–996 (2001).
   PubMed Web of Science ®Google Scholar
• Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA290, 2976–2984 (2003).
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.60, 406–409 (2007).
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Want YF et al. Emergency of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft tissue infections. Ann. Intern. Med.26, 166–174 (2006).
   Google Scholar
• Frazee BW, Lynn J, Charlebois ED et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med.45, 311–320 (2005).
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Hoban DJ, Johnson BM et al.In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST) program 2004. Diagn. Microbiol. Infect. Dis.52, 181–186 (2005).
   PubMed Web of Science ®Google Scholar